Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells

Journal of Neuro-Oncology

Volumn 92, Issue 1, 2009, Pages 15-22

  Oi, Sachie ^a   Natsume, Atsushi ^a   Ito, Motokazu ^a   Kondo, Yutaka ^b   Shimato, Shinji ^a   Maeda, Yuka ^a   Saito, Kiyoshi ^a   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

DNA methylation; Glioma; Histonede acetylase inhibitor; NY ESO 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE H3; LYSINE; NY ESO 1 ANTIGEN; VALPROIC ACID;

ACETYLATION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG POTENTIATION; DRUG TARGETING; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN MODIFICATION;

ANTIGENS, NEOPLASM; AZACITIDINE; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION; GLIOMA; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 59349096447     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9732-0     Document Type: Article

References (20)

1. Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918. doi: 10.1073/ pnas.94.5.1914
2. Boon T, Cerottini JC, Van den Eynde B et al (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365. doi: 10.1146/ annurev.iy.12.040194.002005
3. Jager E, Nagata Y, Gnjatic S et al (2000) Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760-4765. doi: 10.1073/ pnas.97.9.4760
4. dos Santos NR, Torensma R, de Vries TJ et al (2000) Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 60:1654-1662
5. Natsume A, Wakabayashi T, Tsujimura K et al (2008) The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122:2542-2553
6. Cameron EE, Bachman KE, Myohanen S et al (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107. doi: 10.1038/5047
7. Nguyen CT, Weisenberger DJ, Velicescu M et al (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62:6456-6461
8. Suzuki H, Gabrielson E, Chen W et al (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31:141-149. doi: 10.1038/ng892
9. Cheung P, Lau P (2005) Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 19:563-573
10. Richon VM, O'Brien JP (2002) Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8:662-664
11. Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463. doi: 10.1038/ nature02625
12. Lehrman G, Hogue IB, Palmer S et al (2005) Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 366:549-555. doi: 10.1016/S0140-6736(05)67098-5
13. Phiel CJ, Zhang F, Huang EY et al (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741. doi: 10.1074/ jbc.M101287200
14. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206-215. doi: 10.1128/MCB.23.1.206-215.2003
15. Chen YT, Boyer AD, Viars CS et al (1997) Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 79:237-240. doi: 10.1159/000134734
16. Santos-Rosa H, Schneider R, Bannister AJ et al (2002) Active genes are tri-methylated at K4 of histone H3. Nature 419:407-411. doi: 10.1038/ nature01080
17. Marks PA, Miller T, Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3:344-351. doi: 10.1016/S1471-4892(03)00084-5
18. Gottlicher M, Minucci S, Zhu P et al (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. doi: 10.1093/emboj/20.24.6969
19. Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: Causes and therapies. Nat Rev 1:194-202
20. Acharya MR, Sparreboom A, Venitz J et al (2005) Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 68:917-932. doi: 10.1124/mol.105.014167